377 related articles for article (PubMed ID: 33737342)
1. Human CD141
Lee YS; O'Brien LJ; Walpole CM; Pearson FE; Leal-Rojas IM; Masterman KA; Atkinson V; Barbour A; Radford KJ
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737342
[TBL] [Abstract][Full Text] [Related]
2. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
[TBL] [Abstract][Full Text] [Related]
3. Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141
Masterman KA; Haigh OL; Tullett KM; Leal-Rojas IM; Walpole C; Pearson FE; Cebon J; Schmidt C; O'Brien L; Rosendahl N; Daraj G; Caminschi I; Gschweng EH; Hollis RP; Kohn DB; Lahoud MH; Radford KJ
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32737142
[TBL] [Abstract][Full Text] [Related]
4. Skin dendritic cells in melanoma are key for successful checkpoint blockade therapy.
Prokopi A; Tripp CH; Tummers B; Hornsteiner F; Spoeck S; Crawford JC; Clements DR; Efremova M; Hutter K; Bellmann L; Cappellano G; Cadilha BL; Kobold S; Boon L; Ortner D; Trajanoski Z; Chen S; de Gruijl TD; Idoyaga J; Green DR; Stoitzner P
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33408092
[TBL] [Abstract][Full Text] [Related]
5. T cell infiltration on local CpG-B delivery in early-stage melanoma is predominantly related to CLEC9A
Koster BD; López González M; van den Hout MF; Turksma AW; Sluijter BJ; Molenkamp BG; van Leeuwen PA; Vosslamber S; Scheper RJ; van den Eertwegh AJ; van den Tol MP; Jordanova EJ; de Gruijl TD
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737341
[TBL] [Abstract][Full Text] [Related]
6. Activation of human CD141
Pearson FE; Chang K; Minoda Y; Rojas IML; Haigh OL; Daraj G; Tullett KM; Radford KJ
Immunol Cell Biol; 2018 Apr; 96(4):390-400. PubMed ID: 29344995
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models.
Rosato RR; Dávila-González D; Choi DS; Qian W; Chen W; Kozielski AJ; Wong H; Dave B; Chang JC
Breast Cancer Res; 2018 Sep; 20(1):108. PubMed ID: 30185216
[TBL] [Abstract][Full Text] [Related]
8. Skin-Grafting and Dendritic Cell "Boosted" Humanized Mouse Models Allow the Pre-Clinical Evaluation of Therapeutic Cancer Vaccines.
Zeng B; Moi D; Tolley L; Molotkov N; Frazer IH; Perry C; Dolcetti R; Mazzieri R; Cruz JLG
Cells; 2023 Aug; 12(16):. PubMed ID: 37626903
[TBL] [Abstract][Full Text] [Related]
9. The In Vitro Differentiation of Human CD141+CLEC9A+ Dendritic Cells from Mobilized Peripheral Blood CD34+ Hematopoietic Stem Cells.
Swartz AM; Nair SK
Curr Protoc; 2022 Apr; 2(4):e410. PubMed ID: 35435334
[TBL] [Abstract][Full Text] [Related]
10. FLT3-ligand treatment of humanized mice results in the generation of large numbers of CD141+ and CD1c+ dendritic cells in vivo.
Ding Y; Wilkinson A; Idris A; Fancke B; O'Keeffe M; Khalil D; Ju X; Lahoud MH; Caminschi I; Shortman K; Rodwell R; Vuckovic S; Radford KJ
J Immunol; 2014 Feb; 192(4):1982-9. PubMed ID: 24453245
[TBL] [Abstract][Full Text] [Related]
11. Human CD141
Minoda Y; Virshup I; Leal Rojas I; Haigh O; Wong Y; Miles JJ; Wells CA; Radford KJ
Front Immunol; 2017; 8():1419. PubMed ID: 29163495
[TBL] [Abstract][Full Text] [Related]
12. Comparison of two routes of administration of a cationic liposome formulation for a prophylactic DC vaccination in a murine melanoma model.
Yazdani M; Nikpoor AR; Gholizadeh Z; Mohamadian Roshan N; Seifalian A; Jaafari MR; Badiee A
Int Immunopharmacol; 2021 Sep; 98():107833. PubMed ID: 34352472
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma.
Saberian C; Amaria RN; Najjar AM; Radvanyi LG; Haymaker CL; Forget MA; Bassett RL; Faria SC; Glitza IC; Alvarez E; Parshottam S; Prieto V; Lizée G; Wong MK; McQuade JL; Diab A; Yee C; Tawbi HA; Patel S; Shpall EJ; Davies MA; Hwu P; Bernatchez C
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34021033
[TBL] [Abstract][Full Text] [Related]
14. Modulation of lactate-lysosome axis in dendritic cells by clotrimazole potentiates antitumor immunity.
Wang Z; Xu F; Hu J; Zhang H; Cui L; Lu W; He W; Wang X; Li M; Zhang H; Xiong W; Xie C; Liu Y; Zhou P; Liu J; Huang P; Qin XF; Xia X
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016722
[TBL] [Abstract][Full Text] [Related]
15. Quantitative and qualitative impairments in dendritic cell subsets of patients with ovarian or prostate cancer.
Mastelic-Gavillet B; Sarivalasis A; Lozano LE; Wyss T; Inoges S; de Vries IJM; Dartiguenave F; Jichlinski P; Derrè L; Coukos G; Melero I; Harari A; Romero P; Viganó S; Kandalaft LE
Eur J Cancer; 2020 Aug; 135():173-182. PubMed ID: 32590296
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of dendritic cell-based immunotherapy produced from cord blood in vitro and in a humanized NSG mouse cancer model.
Liu G; Fan X; Cai Y; Fu Z; Gao F; Dong J; Li K; Cai J
Immunotherapy; 2019 May; 11(7):599-616. PubMed ID: 30943862
[TBL] [Abstract][Full Text] [Related]
17. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
[TBL] [Abstract][Full Text] [Related]
18. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma.
Daud AI; Loo K; Pauli ML; Sanchez-Rodriguez R; Sandoval PM; Taravati K; Tsai K; Nosrati A; Nardo L; Alvarado MD; Algazi AP; Pampaloni MH; Lobach IV; Hwang J; Pierce RH; Gratz IK; Krummel MF; Rosenblum MD
J Clin Invest; 2016 Sep; 126(9):3447-52. PubMed ID: 27525433
[TBL] [Abstract][Full Text] [Related]
19. New Therapeutic Approaches for Conjunctival Melanoma-What We Know So Far and Where Therapy Is Potentially Heading: Focus on Lymphatic Vessels and Dendritic Cells.
Peil J; Bock F; Kiefer F; Schmidt R; Heindl LM; Cursiefen C; Schlereth SL
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163401
[TBL] [Abstract][Full Text] [Related]
20. Targeted Co-delivery of Tumor Antigen and α-Galactosylceramide to CD141
Huang J; Zhou J; Ghinnagow R; Seki T; Iketani S; Soulard D; Paczkowski P; Tsuji Y; MacKay S; Cruz LJ; Trottein F; Tsuji M
Front Immunol; 2020; 11():2043. PubMed ID: 32973811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
